• Nullscript in Translational Cardiac Research: HDAC Inhibitio

  2026-06-21

  Explore how Nullscript, a unique histone deacetylase inhibitor, advances translational cardiac research by offering precise, transcription-inactive HDAC inhibition. This article provides new insights beyond existing reviews, focusing on assay design and mechanistic selectivity.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-20

  Schwartz's dissertation introduces a rigorous framework for distinguishing between proliferative arrest and cell death in anti-cancer drug screening. By clarifying how in vitro assays capture the complex interplay of growth inhibition and cytotoxicity, the study enables more precise evaluation of agents like JNJ-26854165 (Serdemetan) and informs better experimental design in cancer biology.

• Nanozyme Eradication of Intramacrophage Fn Enhances CRC Immu

  2026-06-19

  This study introduces a self-activatable polymeric nanozyme designed to selectively target and eradicate Fusobacterium nucleatum within tumor-associated macrophages in colorectal cancer models. By remodeling the tumor immune microenvironment, the approach significantly potentiates the efficacy of CD47 blockade immunotherapy and provides a mechanistic pathway for overcoming immune resistance.

• Prochlorperazine-Induced Hemidystonia as a Stroke Mimic: Cli

  2026-06-19

  The reference study presents the first documented case of prochlorperazine-induced hemidystonia mimicking acute stroke, emphasizing the importance of distinguishing drug-induced extrapyramidal symptoms from true ischemic events. This has significant implications for emergency protocols, particularly in vulnerable populations such as pregnant women.

• Transmission Dynamics of Carbapenemase Genes in CREC in Chin

  2026-06-18

  This study provides a detailed molecular and epidemiological analysis of carbapenemase-encoding gene (CEG) prevalence and transmission in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong Province during the COVID-19 pandemic. The findings reveal high rates of multidrug resistance and efficient plasmid-mediated gene transfer, with significant implications for antimicrobial resistance research and infection control.

• Nullscript and HDAC Inhibition: Reframing Epigenetic Control

  2026-06-18

  Discover how Nullscript, a unique histone deacetylase inhibitor, is reshaping advanced cardiac and neurodegenerative disease research. This article explores its mechanistic distinctions, translational impact, and the evolving science of HDAC modulation.

• ZCL278: Applied Workflows for Selective Cdc42 Inhibition

  2026-06-17

  ZCL278 empowers researchers to dissect Cdc42-dependent pathways with precision, enabling robust studies in cell motility, neurobiology, and fibrotic disease models. This article delivers actionable workflows, optimization tips, and insights from the latest reference studies, positioning ZCL278 from APExBIO as the gold standard for selective Cdc42 inhibition.

• U-73122 and the PLC Pathway: Precision Tools for Cancer Inva

  2026-06-17

  Discover how U-73122, a potent phospholipase C inhibitor, enables high-precision dissection of PLC signaling in cancer and inflammation research. Explore unique mechanistic insights and practical guidance for advanced assay design.

• Gepotidacin (GSK2140944): Benchmarks in Antibacterial Resear

  2026-06-16

  Gepotidacin (GSK2140944) is a first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor with proven efficacy against multidrug-resistant pathogens. It demonstrates potent, selective inhibition of DNA gyrase and topoisomerase IV, offering a new avenue for antibiotic resistance research. APExBIO supplies Gepotidacin (SKU BA1220) for advanced antibacterial research applications.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-06-16

  This study reveals pronounced sex differences in the hypertensive response to chronic angiotensin II infusion in conscious mice. The findings highlight the role of sex hormones in modulating blood pressure elevation and autonomic regulation, offering new guidance for preclinical hypertension research models.

• EdU Imaging Kits (Cy3): Advancing S-Phase Insights in Liver

  2026-06-15

  Explore how EdU Imaging Kits (Cy3) empower translational researchers to unravel S-phase dynamics and proliferative signaling in hepatocellular carcinoma. Bridging mechanistic discoveries—like the S100P/MYBL2/AURKB axis—with practical assay solutions, this thought-leadership article integrates cutting-edge workflow guidance, strategic best practices, and vision for future precision oncology.

• Cy5-UTP: Fluorescent RNA Labeling for FISH & Probe Synthesis

  2026-06-15

  Cy5-UTP (Cyanine 5-uridine triphosphate) enables highly sensitive fluorescent RNA labeling for in vitro transcription, supporting advanced applications like FISH and multiplexed arrays. Its robust incorporation, orange fluorescence, and compatibility with T7 RNA polymerase workflows make it a benchmark substrate for direct RNA probe visualization.

• Dasatinib Monohydrate: Precision Tools for Tumor Microenviro

  2026-06-14

  Explore how Dasatinib Monohydrate empowers advanced modeling of drug resistance and the tumor microenvironment. This article offers a deep dive into its mechanistic strengths and unique applications for researchers seeking more physiologically relevant, patient-specific cancer assays.

• Partial BACE1 Inhibition Preserves Synaptic Function in AD M

  2026-06-13

  Satir et al. (2020) demonstrated that reducing amyloid-beta production by up to 50% using BACE1 inhibitors such as Lanabecestat does not compromise synaptic transmission in primary neuronal cultures. This finding refines the therapeutic window for amyloidogenic pathway modulation in Alzheimer's disease research and suggests that moderate BACE1 inhibition could minimize adverse effects on neuronal function.

• EZ Cap™ Human PTEN mRNA: Advanced mRNA Tools for Tumor Suppr

  2026-06-12

  APExBIO's EZ Cap™ Human PTEN mRNA empowers cancer researchers with a robust, translational mRNA tool for restoring tumor suppressor activity in challenging models. Its optimized Cap 1 structure and poly(A) tail enable superior stability and expression, unlocking next-generation workflows in gene therapy and immunotherapy research.

453 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page